Quick Takeaways
- Almitas Capital LLC filed SCHEDULE 13G for AN2 Therapeutics, Inc. Common Stock and Warrants (ANTX).
- Disclosed ownership: 5.2%.
- Date of event: 30 Sep 2025.
Almitas Capital LLC - 30 Sep 2025 SCHEDULE 13G Report for AN2 Therapeutics, Inc. Common Stock and Warrants (ANTX)
- Filing Manager
- Almitas Capital LLC
- Reporting Manager
- Almitas Capital LLC
- Symbol
- ANTX
- Shares outstanding
- 27,467,750 shares
- Disclosed Ownership
- 1,428,323 shares
- Ownership
- 5.2%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Nov 2025, 19:51:37 UTC
- Date of event
- 30 Sep 2025
- Next filing
- 17 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Almitas Capital LLC disclosed 5.2% ownership in AN2 Therapeutics, Inc. Common Stock and Warrants (ANTX) on 30 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Nov 2025, 19:51.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Almitas Capital LLC | 5.2% | 1,428,323 | 1,428,323 | 0 | Ronald Mass | Managing Principal |